Listed by the USPTO as IVICH, FERNANDO NMN
Tech Center 1600 • Art Units: 1600 1657 1658 1674 1678 1682
This examiner grants 52% of resolved cases
IVICH, FERNANDO NMN is a USPTO patent examiner in Tech Center 1600 and Art Unit 1600. The record includes 42 resolved cases, with an allowance rate of 52.4% and a median of 1491 days to allowance. The interview lift is 72.2%, the largest reported interview metric in this profile.
The listed companies are Cytek Biosciences Inc., Hoffmann-La Roche Inc., and Bristol-Myers Squibb Company. The listed firms are Alford Law Group, Inc., DINSMORE & SHOHL LLP, and NIXON & VANDERHYE, PC. Practitioners can view the 72.2% interview lift as a central prosecution signal, while the 52.4% allowance rate and 1491-day median provide context for expected case progression. The 42-case record remains the relevant scope for interpreting these figures.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17488649 | SPR-BASED BINDING ASSAY FOR THE FUNCTIONAL ANALYSIS OF MULTIVALENT MOLECULES | Non-Final OA | Hoffmann-La Roche Inc. |
| 17760692 | DUAL CAPTURE METHOD FOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18442934 | COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17619958 | IMMUNE CELL SIGNATURE FOR BACTERIAL SEPSIS | Non-Final OA | The General Hospital Corporation |
| 17997878 | DETECTION ASSAY FOR ANTI-SARS-COV-2 ANTIBODIES | Non-Final OA | The Regents of the University of California |
| 18383393 | METHODS OF IMPROVING NEURODEGENERATIVE DISORDERS BY TARGETED DELIVERY OF THERAPEUTIC AGENTS | Final Rejection | West Virginia University Board of Governors on behalf of West Virginia University |
| 18012798 | PROGNOSIS OF CHRONIC INFLAMMATORY DEMYELINATING POLY-NEUROPATHY | Non-Final OA | Katholieke Universiteit Leuven |
| 17618869 | TARGETS AND METHODS OF DIAGNOSING, MONITORING AND TREATING FRONTOTEMPORAL DEMENTIA | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17598015 | MAGNETIC RESPONSIVE PARTICLE AND IMMUNOASSAY METHOD USING SAME, REAGENT FOR IMMUNOASSAY | Non-Final OA | SEKISUI MEDICAL CO., LTD. |
| 18044344 | BIOSENSOR FOR DETECTING STRUCTURAL CHANGES IN HUMAN CARDIAC MUSCLE PROTEIN | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17266029 | METHOD FOR CULTURING CANCER TISSUE OR TISSUE ANALOGOUS TO CANCER TISSUE | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18043610 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | Final Rejection | ASCENTAWITS PHARMACEUTICALS, LTD. |
| 17918686 | METHOD FOR PREDICTING THE RETURN TO FUNCTIONAL AUTONOMY IN A SUBJECT SUFFERING FROM AN ACUTE EVENT | Non-Final OA | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy52.4% of resolved applications examined by Fernando Nmn Ivich were allowed (42 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +72.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Fernando Nmn Ivich took 1,491 days on average from filing to allowance.
Fernando Nmn Ivich examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
